Skip to Main Content

ATLANTA — The American Society of Hematology’s annual meeting here has been buzzing about CAR-T therapies. New data show the treatment’s effects can be quite durable — at least for some patients — and suggest that it might be safe to administer some CAR-Ts on an outpatient basis.

For some insight into the early rollout of one of the first CAR-Ts to hit the market, STAT sat down for a quick interview with Dr. David Chang, the chief medical officer of Kite, now a part of Gilead Sciences (GILD).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.